Optimizing syngeneic orthotopic murine bladder cancer (MB49)

Cancer Research

Volumn 59, Issue 12, 1999, Pages 2834-2837

  Günther, Jan H ^b   Jurczok, Andreas ^b   Wulf, Tina ^b   Brandau, Sven ^b   Deinert, Irina ^b   Jocham, Dieter ^b   Böhle, Andreas ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CANCER SURVIVAL; CANCER TRANSPLANTATION; FEMALE; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; TUMOR MODEL;

ANIMALS; BCG VACCINE; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; ORGAN SIZE; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0345711634     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Soloway, M. S. Single and combination chemotherapy for primary murine bladder cancer. Cancer (Phila.), 36: 333-340, 1975.
2. Williams, P. D., and Murphy, G. P. Experimental bladder tumor induction, propagation and therapy. Urology, 8: 39-42, 1976.
3. Hubbell, H. R., Kvalnes-Krick, K., and Carter, W. G. Antiproliferative and immunomodulatory actions of β-interferon and double-stranded RNA, individually and in combination, on human bladder tumor xenografts in nude mice. Cancer Res., 45: 2481-2486, 1985.
4. Huland, H., Otto, U., and von Paleske, A. Chemotherapy and human bladder carcinoma transplanted into NMRI nu/nu mice. J. Urol., 134: 601-606, 1985.
5. Russell, P. J., Raghavan, D., Gregory, P., Philips, J., Wills, E. J., Jelbart, M., Wass, J., Zbroja, R. A., and Vincent, P. C. Bladder cancer xenografts: a model of tumor cell heterogeneity. Cancer Res., 46: 2035-2040, 1986.
6. Ratliff, T. L., Gillen, D. P., and Catalona, W. J. Requirement of a thymus-dependent immune response for BCG-mediated antitumor activity. J. Urol., 137: 155-158, 1987.
7. Hudson, M. A., Ritchey, J. K., Catalona, W. J., Brown, E. J., and Ratliff, T. L. Comparison of the fibronectin-binding ability and antitumor efficacy of various mycobacteria. Cancer Res., 50: 3843-3847, 1990.
8. Soloway, M. Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res., 37: 2918-2929, 1977.
9. Lee, K-E., Weiss, G. H., O'Donnell, R. W., and Cockett, A. T. K. Reduction of bladder cancer growth in mice treated with intravesical Bacillus Calmette-Guérin and systemic interleukin 2. J. Urol., 137: 1270-1273, 1987.
10. Shapiro, A., Ratliff, T. L., Oakley, D. M., and Catalona, W. J. Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity. Cancer Res., 41: 1611-1615, 1983.
11. Shapiro, A., Ratliff, T. L., Oakley, D. M., and Catalona, W. J. Comparison of the efficacy of intravesical Bacillus Calmette-Guérin with thiotepa, mitomycin C, poly 1:C/poly-l-lysine and cisplatinum in murine bladder cancer. J. Urol., 131: 139-142, 1984.
12. Summerhayes, I. C., and Franks, L. M. Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. J. Natl. Cancer Inst. (Bethesda), 62: 1017-1023, 1979.
13. Soloway, M. S., and Masters, S. Urothelial susceptibility to tumor cell implantation. Influence of cauterization. Cancer (Phila.), 46: 1158-1158, 1980.
14. Shapiro, A., Kelley, D. R., Oakley, D. M., Catalona, W. J., and Ratliff, T. L. Technical factors affecting the reproducibility of intravesical mouse bladder tumor implantation during therapy with Bacillus Calmette-Guérin. Cancer Res., 44: 3051-3054, 1984.
15. Swerdlow, R. D., Ratliff, T. L., Regina, M. L., Ritchey, J. K., and Ebert, R. F. Immunotherapy with keyhole limpet hemocyanin: efficacy and safety in the MB-49 intravesical murine bladder tumor model. J. Urol., 151: 1718-1722, 1994.
16. Alexander, A. A., Liu, J. B., McCue, P., Gomella, L. G., Ross, R. P., and Lattime, E. C. Intravesical growth of murine bladder tumors assessed by transrectal ultrasound. J. Urol., 150: 525-528, 1993.
17. Soloway, M. S., Nissenkorn, I., and McCallum, L. Urothelial susceptibility to tumor cell implantation: comparison of cauterization with N-methyl-N-nitrosourea. Urology, 21: 159-161, 1983.
18. Chin, J. L., Kadhim, S. A., Batislam, E., Karlik, S. J., Garcia, B. M., Nickel, J. C., and Morales, A. Mycobacterium cell wall: an alternative to intravesical Bacillus Calmette-Guérin (BCG) therapy in orthotopic murine bladder cancer. J. Urol., 156: 1189-1193, 1996.
19. Chin, J., Kadhim, S., Garcia, B., Kim, Y. S., and Karlik, S. Magnetic resonance imaging for detecting and treatment monitoring of orthotopic murine bladder tumor implants. J. Urol., 145: 1297-1301, 1991.
20. Jiang, F., and Zhou, X-M. A model of orthotopic murine bladder (MBT-2) tumor implants. Urol. Res., 25: 179-182, 1997.